| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/11/2024 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | NASDAQ:SPRO | Spero Therapeutics Inc |
| 12/11/2024 | 22:05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SPRO | Spero Therapeutics Inc |
| 07/11/2024 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 | NASDAQ:SPRO | Spero Therapeutics Inc |
| 29/10/2024 | 22:01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SPRO | Spero Therapeutics Inc |
| 29/10/2024 | 21:05 | GlobeNewswire Inc. | Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update | NASDAQ:SPRO | Spero Therapeutics Inc |
| 16/10/2024 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 | NASDAQ:SPRO | Spero Therapeutics Inc |
| 02/10/2024 | 22:30 | GlobeNewswire Inc. | Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy | NASDAQ:SPRO | Spero Therapeutics Inc |
| 04/09/2024 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics to Present at Upcoming September Investor Conferences | NASDAQ:SPRO | Spero Therapeutics Inc |
| 05/08/2024 | 22:25 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:SPRO | Spero Therapeutics Inc |
| 05/08/2024 | 22:18 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SPRO | Spero Therapeutics Inc |
| 05/08/2024 | 22:01 | GlobeNewswire Inc. | Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update | NASDAQ:SPRO | Spero Therapeutics Inc |
| 29/07/2024 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024 | NASDAQ:SPRO | Spero Therapeutics Inc |
| 03/07/2024 | 19:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:SPRO | Spero Therapeutics Inc |
| 15/05/2024 | 13:50 | IH Market News | U.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices Drop | NASDAQ:SPRO | Spero Therapeutics Inc |
| 06/03/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 | NASDAQ:SPRO | Spero Therapeutics Inc |
| 28/02/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections | NASDAQ:SPRO | Spero Therapeutics Inc |
| 26/02/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference | NASDAQ:SPRO | Spero Therapeutics Inc |
| 05/02/2024 | 22:50 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:SPRO | Spero Therapeutics Inc |
| 31/01/2024 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:SPRO | Spero Therapeutics Inc |
| 05/01/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics Provides Corporate Update and 2024 Outlook | NASDAQ:SPRO | Spero Therapeutics Inc |
| 02/01/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections | NASDAQ:SPRO | Spero Therapeutics Inc |
| 15/11/2023 | 22:15 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:SPRO | Spero Therapeutics Inc |
| 13/11/2023 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update | NASDAQ:SPRO | Spero Therapeutics Inc |
| 13/11/2023 | 12:45 | IH Market News | Monday’s Wall Street Highlights: Boeing, Novo Nordisk, Moody’s, StoneCo, and more | NASDAQ:SPRO | Spero Therapeutics Inc |
| 06/11/2023 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 | NASDAQ:SPRO | Spero Therapeutics Inc |
| 01/11/2023 | 21:05 | GlobeNewswire Inc. | Spero Therapeutics to Present at Upcoming November Investor Conferences | NASDAQ:SPRO | Spero Therapeutics Inc |
| 01/11/2023 | 13:05 | GlobeNewswire Inc. | Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer | NASDAQ:SPRO | Spero Therapeutics Inc |
| 16/10/2023 | 22:01 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:SPRO | Spero Therapeutics Inc |
| 20/09/2023 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference | NASDAQ:SPRO | Spero Therapeutics Inc |
| 06/09/2023 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference | NASDAQ:SPRO | Spero Therapeutics Inc |